About NRx Pharmaceuticals, Inc.
https://www.nrxpharma.comNRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
CEO
Jonathan C. Javitt
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-02 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
ANSON FUNDS MANAGEMENT LP
Shares:2.03M
Value:$4.35M
VANGUARD GROUP INC
Shares:534.96K
Value:$1.15M
ADVISORSHARES INVESTMENTS LLC
Shares:342.14K
Value:$735.59K
Summary
Showing Top 3 of 30
About NRx Pharmaceuticals, Inc.
https://www.nrxpharma.comNRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $242K ▲ | $4.17M ▲ | $-5.89M ▲ | -2.43K% ▼ | $-0.27 ▲ | $-5.85M ▲ |
| Q2-2025 | $0 | $3.73M ▼ | $-17.58M ▼ | 0% | $-0.98 ▼ | $-17.58M ▼ |
| Q1-2025 | $0 | $3.85M ▲ | $-5.51M ▲ | 0% | $-0.34 ▲ | $-5.51M ▲ |
| Q4-2024 | $0 | $3.63M ▲ | $-9.08M ▼ | 0% | $-0.86 ▼ | $-9.08M ▼ |
| Q3-2024 | $0 | $3.02M | $-1.62M | 0% | $-0.15 | $-1.62M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $7.18M ▲ | $15M ▲ | $40.75M ▲ | $-25.75M ▲ |
| Q2-2025 | $2.91M ▼ | $4.84M ▼ | $40.45M ▲ | $-35.62M ▼ |
| Q1-2025 | $5.55M ▲ | $7.59M ▲ | $32.75M ▲ | $-25.16M ▼ |
| Q4-2024 | $1.44M ▼ | $3.65M ▼ | $26.87M ▲ | $-23.22M ▼ |
| Q3-2024 | $1.65M | $4.46M | $23.28M | $-18.82M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.89M ▲ | $-2.89M ▲ | $-2.56M ▼ | $9.73M ▲ | $4.27M ▲ | $-2.89M ▲ |
| Q2-2025 | $-17.58M ▼ | $-4.03M ▼ | $0 | $1.39M ▼ | $-2.64M ▼ | $-4.03M ▼ |
| Q1-2025 | $-5.51M ▲ | $-3.48M ▼ | $0 | $7.58M ▲ | $4.11M ▲ | $-3.48M ▼ |
| Q4-2024 | $-9.08M ▼ | $-1.46M ▲ | $0 | $1.26M ▼ | $-203K ▲ | $-1.46M ▲ |
| Q3-2024 | $-1.62M | $-2.31M | $0 | $2.05M | $-252K | $-2.31M |
CEO
Jonathan C. Javitt
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-02 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 3 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
ANSON FUNDS MANAGEMENT LP
Shares:2.03M
Value:$4.35M
VANGUARD GROUP INC
Shares:534.96K
Value:$1.15M
ADVISORSHARES INVESTMENTS LLC
Shares:342.14K
Value:$735.59K
Summary
Showing Top 3 of 30